Australian company studying impact of rare cannabinoids on autism
Article content An Australian-based company with an exclusive licence to a variety of rare cannabis cultivars is putting its plants to the test. Neurotech International (NTI) has begun a study to assess the safety and tolerability of its products to treat symptoms associated with autism in children. We apologize, but this video has failed to load. Try refreshing your browser, or Australian company studying impact of rare cannabinoids on autism Back to video In a release, the company reported it is currently working on a Phase I/II open label clinical study in 20 children aged five to 17 who...
Source: lfpress.com